NASH Contender Inventiva Backed By Euronext IPO
Executive Summary
The five-year-old French biotech Inventiva Pharma has raised financing on the public markets to propel its lead fibrosis/NASH product through the development pipeline.
You may also be interested in...
NASH Companies Take The Stage At AASLD
NGM’s injectable might be best-suited as induction therapy for sicker NASH patients, Inventiva hopes its pan-PPAR agonist will outperform Genfit’s elafibranor, and Albireo thinks IBAT inhibition offers promise in NASH.
Cirius Suspects Insulin Resistance Is Underlying Key To NASH
The former Octeta is expanding the ongoing Phase IIb study of its second-generation insulin sensitizer. An insulin sensitizer with a better safety profile than first-generation drugs like Actos may provide a backbone therapy for NASH, the company believes.
Intercept Increases Chance Of Success In NASH Without Significant Delay
Ocaliva could now qualify for accelerated approval in NASH by meeting either of two Phase III co-primary endpoints, whereas the trial initially was designed for success on both measures.